TG Therapeutics (TGTX) to Release Earnings on Monday

TG Therapeutics (NASDAQ:TGTX) is anticipated to issue its Q4 2025 results before the market opens on Monday, March 2nd. Analysts expect the company to announce earnings of $0.38 per share for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Friday, March 6, 2026 at 9:30 AM ET.

TG Therapeutics Trading Up 0.2%

TGTX opened at $29.53 on Monday. The stock has a market capitalization of $4.69 billion, a PE ratio of 10.62 and a beta of 1.85. TG Therapeutics has a one year low of $25.28 and a one year high of $46.48. The company has a debt-to-equity ratio of 0.40, a quick ratio of 2.89 and a current ratio of 3.82. The business’s 50 day moving average price is $29.90 and its 200 day moving average price is $31.37.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Danske Bank A S acquired a new stake in TG Therapeutics during the 3rd quarter worth approximately $25,000. EverSource Wealth Advisors LLC increased its position in shares of TG Therapeutics by 86.3% during the second quarter. EverSource Wealth Advisors LLC now owns 1,237 shares of the biopharmaceutical company’s stock worth $45,000 after acquiring an additional 573 shares during the period. Truvestments Capital LLC raised its stake in shares of TG Therapeutics by 172.4% in the fourth quarter. Truvestments Capital LLC now owns 1,621 shares of the biopharmaceutical company’s stock valued at $48,000 after acquiring an additional 1,026 shares in the last quarter. Kemnay Advisory Services Inc. purchased a new position in TG Therapeutics in the fourth quarter valued at $52,000. Finally, Johnson Financial Group Inc. boosted its holdings in TG Therapeutics by 199.1% in the third quarter. Johnson Financial Group Inc. now owns 2,055 shares of the biopharmaceutical company’s stock valued at $74,000 after purchasing an additional 1,368 shares during the period. Institutional investors and hedge funds own 58.58% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on TGTX shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of TG Therapeutics in a research note on Wednesday, January 14th. B. Riley Financial raised shares of TG Therapeutics to a “strong-buy” rating in a research report on Tuesday, November 4th. The Goldman Sachs Group increased their target price on shares of TG Therapeutics from $37.00 to $39.00 and gave the stock a “neutral” rating in a research note on Thursday, January 15th. JPMorgan Chase & Co. reduced their price target on shares of TG Therapeutics from $49.00 to $46.00 and set an “overweight” rating on the stock in a research note on Monday, February 2nd. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of TG Therapeutics in a report on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $50.00.

About TG Therapeutics

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.